Also known as: Eldepryl API; L-Deprenyl; Selegiline HCl
Selegiline is a selective monoamine oxidase B (MAO-B) inhibitor and active pharmaceutical ingredient used in the treatment of Parkinson's disease. Mediocon Inc supplies high-purity Selegiline API conforming to BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.
Selegiline selectively inhibits MAO-B at therapeutic doses, preventing the breakdown of dopamine in the striatum and thereby extending dopaminergic activity. It is used as an adjunct to levodopa therapy in Parkinson's disease and has neuroprotective properties.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Selegiline (CAS 14611-51-9) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Selegiline is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance